Pipeline Therapeutics, Inc. Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2017)

Organization Overview

First Clinical Trial
2020
NCT04462198
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Chief Medical Officer, Pipeline Therapeutics, Inc | Chief Medical Officer, Pipeline Therapeutics, Inc. | Pipeline Therapeutics, Inc. | Stemline Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

pipe-505 (1 trial)

Drugs in Phase 1 Trials (1)

pipe-307 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Deafness (Phase 2)

Hearing Loss (Phase 2)

Hearing Loss, Sensorineural (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2